What are the possible adverse effects of vascepa combination?

Vascepa (icosapent ethyl) is approved to reduce cardiovascular risk in adults with elevated triglycerides and other risk factors, often used alongside statins. Common adverse effects include:

- Musculoskeletal pain (up to 5% of patients).
- Peripheral edema (up to 3%).
- Constipation (up to 3%).
- Atrial fibrillation (up to 5%).
- Increased bleeding risk, especially with anticoagulants or antiplatelets.

When combined with statins (a frequent pairing), risks rise for:

- Myopathy or rhabdomyolysis (muscle breakdown), though rare.
- Elevated liver enzymes.
- New-onset diabetes or glycemic control issues in predisposed patients.

Gastrointestinal issues like nausea or diarrhea occur in 3-5% overall. Serious risks include hemorrhagic stroke or hypersensitivity reactions. Monitor for gout flares due to uric acid changes. Full details appear in the prescribing information; consult a healthcare provider for personalized risks.

Sources:
- [1] Vascepa Prescribing Information, Amarin Pharma (https://www.vascepa.com/)
- [2] FDA Label for Vascepa (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202057s019lbl.pdf)